Guardant Health, Inc. - Common Stock (NQ:GH)

48.87 +1.64 (+3.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,049,999
Open 52.65
Bid (Size) 47.90 (1)
Ask (Size) 48.87 (1)
Prev. Close 47.23
Today's Range 47.09 - 52.92
52wk Range 17.85 - 52.92
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Cathie Wood's Ark Invest Makes Bold $9.8M Robinhood Bet While Dumping Palantir Ahead of Earnings. 
Via Benzinga
Guardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
Diagnostics company Guardant Health (NASDAQ:GH) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue... 
Via StockStory

Performance

YTD
+53.8%
+53.8%
1 Month
+15.1%
+15.1%
3 Month
-2.1%
-2.1%
6 Month
+123.4%
+123.4%
1 Year
+167.6%
+167.6%

More News

Read More
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Earnings Scheduled For April 30, 2025
Via Benzinga
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
From Guardant Health, Inc.
Via Business Wire
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
Via StockStory
Topics World Trade
Exposures Tariff
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Via Benzinga
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
From Guardant Health, Inc.
Via Business Wire
RXO, The Ensign Group, LifeStance Health Group, Surgery Partners, and Guardant Health Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
3 Reasons to Sell GH and 1 Stock to Buy Instead
Via StockStory
Topics Bankruptcy
Exposures Financial Legal
3 of Wall Street’s Favorite Stocks Facing Headwinds
Via StockStory
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
Via Investor's Business Daily
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
From Guardant Health, Inc.
Via Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
Via StockStory
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Via StockStory
3 Small-Cap Stocks in the Doghouse
Via StockStory
4 Healthcare Stocks With Massive Gains—and More to Come
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
The Future of Healthcare: 10 Predictions For The Next Decade
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack
Via StockStory
Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses
Via StockStory
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
From Guardant Health, Inc.
Via Business Wire
1 Healthcare Stock on Our Watchlist and 2 to Turn Down
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?
Yes, Guardant Health, Inc. - Common Stock is publicly traded.
What exchange does Guardant Health, Inc. - Common Stock trade on?
Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Guardant Health, Inc. - Common Stock?
The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market
What is the current price of Guardant Health, Inc. - Common Stock?
The current price of Guardant Health, Inc. - Common Stock is 48.87
When was Guardant Health, Inc. - Common Stock last traded?
The last trade of Guardant Health, Inc. - Common Stock was at 05/01/25 04:00 PM ET
What is the market capitalization of Guardant Health, Inc. - Common Stock?
The market capitalization of Guardant Health, Inc. - Common Stock is 4.95B
How many shares of Guardant Health, Inc. - Common Stock are outstanding?
Guardant Health, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.